ALK is pleased to announce that it has signed an agreement with HealthTrust Purchasing Group, LP to supply PRE-PEN® (benzylpenicilloyl polylysine injection USP) the only FDA approved skin test for the diagnosis of penicillin allergy, to HealthTrust member facilities, including 1,400 acute care facilities, 10,600 ambulatory surgery centers, physician practices and alternate care sites. HealthTrust will incorporate PRE-PEN® (benzylpenicilloyl polylysine injection USP) into its efforts to help reduce the unnecessary use of toxic, broad spectrum antibiotics, which are known to increase drug resistance in patients. The over-use of broad spectrum antibiotics reduces antibiotic effectiveness and can increase the development of drug-resistant germs according to the Centers for Disease Control and Prevention (CDC). According to the CDC antibiotic resistance is one of the world's most pressing public health threats.